Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Movetis Introduces Resolor In UK
Resolor (prucalopride) is a new enterokinetic agent that represents a new approach to the symptomatic treatment of chronic constipation (in women in whom laxatives fail to provide adequate
Resolor (prucalopride) is a new enterokinetic agent that represents a new approach to the symptomatic treatment of chronic constipation (in women in whom laxatives fail to provide adequate
Bionomics has already commenced Phase II testing of the anti-cancer properties of BNC105 in renal cancer in the US. The commencement of these two Phase II trials follows
ALX-0171 is a Nanobody product which binds to RSV and neutralizes the virus. The Nanobody is expected to be administered via lungs and based on the in-vivo data
Access Pharmaceuticals said that MuGard is ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. As
The system is compact (1/3 of a classic granulation line inclusive of a Tablet Press) and has a modular construction allowing it to fit perfectly into any R&D
The new treatment can be used on large areas of skin, including the full face or balding scalp on a convenient, 6-week dosing cycle. Graceway Pharma said that
The patent (USP 7,678,824) entitled ‘Methods for Treatment with Bucindolol Based on Genetic Targeting,’ provides protection in the US for this approach to treat patients with heart failure,
BioStorage Technologies’ facilities will offer its clients the option to utilise Biomatrica’s dry storage technology, which provides security-controlled storage and ensures a stable humidity environment for samples. In
Ondansetron RapidFilm is an oral thin film formulation of ondansetron, a serotonin 5-HT3 receptor antagonist that is commonly used to treat and prevent nausea and vomiting caused by
Salix Pharma said that FDA approval of Xifaxan 550mg tablets was based on a 299 subject, double-blind, placebo-controlled, multinational, Phase 3 clinical trial. Trial results demonstrated a positive